Icagen, the Raleigh-based firm focused on small molecule research with potential for use in new drugs, has landed a deal worth as much as $274 million with drug giant Roche.
Read More
Icagen, which works with clients to “determine drug feasibility using state-of-the-art computational chemistry methods,” is now part of San Diego-based Ligand Pharmaceuticals after a $15 million cash acquisition closed on Thursday.
Read More
Icagen approves raises for CEO and chief scientific officer.
Read More
Drug development company Icagen Inc. raised $7.25 million from one investor, according to a securities filing.
Read MoreIcagen a pharmaceutical development company, continues to raise capital.
Read MoreIcagen Inc.has received an award from the Cystic Fibrosis Foundation worth up to $11 million.
Read MoreIcagen, a pharmaceutical development company, has raised $2 million, according to a securities filing.
Read More
